Morgan Stanley Discloses 5.4% Stake in UroGen Pharma (URGN)

Q: How many UroGen Pharma (URGN) shares does Morgan Stanley hold?

Morgan Stanley reports ownership of 2,488,299 ordinary shares of URGN.

Q: What percentage of URGN鈥檚 outstanding shares does this represent?

The stake equals 5.4% of the outstanding class .

Q: Why was the Schedule 13G filed?

Crossing the 5% ownership threshold on 30 Jun 2025 triggered the mandatory disclosure under SEC rules.

Q: Is Morgan Stanley an activist investor in URGN?

No. The 13G filing indicates a passive investment ; Morgan Stanley states the shares are held in the ordinary course of business.

Q: Does Morgan Stanley have sole voting power over the URGN shares?

It has 0 sole voting power ; voting and dispositive authority are shared.

Q: When was the filing signed and by whom?

The certification was signed by Chris O鈥橦ara on 06 Aug 2025 .

[Form 4] CrowdStrike Holdings, Inc. Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

A Schedule 13G filed by Morgan Stanley reveals a new 5.4% passive stake in UroGen Pharma Ltd. (URGN) as of 30 Jun 2025. The firm reports beneficial ownership of 2,488,299 ordinary shares, all held with shared voting and dispositive power; it claims 0 shares under sole authority. Morgan Stanley is classified as a parent holding company/control person under Rule 13d-1(b).

Crossing the 5% threshold obligates disclosure and often signals increased institutional interest but, because the filing is on Schedule 13G rather than 13D, Morgan Stanley states the investment is made in the ordinary course of business with no intent to influence control. The certification was signed by authorised signatory Chris O鈥橦ara on 6 Aug 2025.

Beneficial ownership: 2.49 M shares
Percent of outstanding class: 5.4%
Event date: 30 Jun 2025; filing date: 6 Aug 2025

Positive

Institutional investor Morgan Stanley now holds 5.4% of URGN, potentially improving stock liquidity and visibility.

Negative

Morgan Stanley reports no sole voting/dispositive power, suggesting limited capacity to advocate for change or support management.

Insights

TL;DR: Morgan Stanley鈥檚 5.4 % passive stake boosts URGN鈥檚 institutional base but offers limited influence; overall impact is modest.

The disclosure meets the 5 % reporting threshold, indicating that a major global financial institution now collectively controls roughly 2.49 M URGN shares. While the position may broaden liquidity and enhance market perception, the Schedule 13G designation confirms the holding is passive; Morgan Stanley retains no sole voting or dispositive power, diminishing prospects for strategic activism. The filing improves transparency but does not materially alter fundamentals or governance dynamics, so the news is noteworthy yet not transformational for valuation.

08/06/2025 - 03:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kurtz George

(Last)

(First)

(Middle)

C/O CROWDSTRIKE HOLDINGS, INC.

206 E. 9TH STREET, SUITE 1400

(Street)

AUSTIN

78701

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CrowdStrike Holdings, Inc. [ CRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock	08/05/2025		S		1,500	D	$439.38⁽¹⁾	2,173,654⁽²⁾	D
Class A common stock	08/05/2025		S		4,500	D	$440.46⁽³⁾	2,169,154⁽²⁾	D
Class A common stock	08/05/2025		S		4,686	D	$441.39⁽⁴⁾	2,164,468⁽²⁾	D
Class A common stock	08/05/2025		S		2,110	D	$442.4⁽⁵⁾	2,162,358⁽²⁾	D
Class A common stock	08/05/2025		S		700	D	$443.3⁽⁶⁾	2,161,658⁽²⁾	D
Class A common stock	08/05/2025		S		807	D	$444.69⁽⁷⁾	2,160,851⁽²⁾	D
Class A common stock	08/05/2025		S		982	D	$445.39⁽⁸⁾	2,159,869⁽²⁾	D
Class A common stock	08/05/2025		S		300	D	$446.56⁽⁹⁾	2,159,569⁽²⁾	D
Class A common stock	08/05/2025		S		342	D	$447.76⁽¹⁰⁾	2,159,227⁽²⁾	D
Class A common stock	08/05/2025		S		358	D	$448.7⁽¹¹⁾	2,158,869⁽²⁾	D
Class A common stock	08/05/2025		S		375	D	$450.24⁽¹²⁾	2,158,494⁽²⁾	D
Class A common stock	08/05/2025		S		500	D	$451.12⁽¹³⁾	2,157,994⁽²⁾	D
Class A common stock	08/05/2025		S		400	D	$452.86⁽¹⁴⁾	2,157,594⁽²⁾	D
Class A common stock	08/05/2025		S		711	D	$453.98⁽¹⁵⁾	2,156,883⁽²⁾	D
Class A common stock	08/05/2025		S		1,034	D	$455⁽¹⁶⁾	2,155,849⁽²⁾	D
Class A common stock	08/05/2025		S		22,362	D	$456.11⁽¹⁷⁾	2,133,487⁽²⁾	D
Class A common stock	08/05/2025		S		500	D	$456.96⁽¹⁸⁾	2,132,987⁽²⁾	D
Class A common stock	08/05/2025		S		100	D	$457.66	2,132,887⁽²⁾	D
Class A common stock								100,000	I	Kurtz Family Dynasty Trust⁽¹⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $438.90 to $439.89. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).

3. This transaction was executed in multiple trades at prices ranging from $439.91 to $440.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $440.92 to $441.88. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $441.92 to $442.89. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $442.99 to $443.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $444.02 to $445.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $445.03 to $445.94. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $446.35 to $446.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $447.35 to $448.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $448.35 to $448.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $449.75 to $450.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $450.78 to $451.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $452.50 to $453.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

15. This transaction was executed in multiple trades at prices ranging from $453.52 to $454.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $454.56 to $455.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

17. This transaction was executed in multiple trades at prices ranging from $455.57 to $456.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

18. This transaction was executed in multiple trades at prices ranging from $456.63 to $457.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

19. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Remarks:

All reported sales were made to cover tax withholdings due on vesting of restricted stock unit awards, as required under the Issuer's administrative policies.

	/s/ Remie Solano, Attorney-in-Fact	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many UroGen Pharma (URGN) shares does Morgan Stanley hold?

Morgan Stanley reports ownership of 2,488,299 ordinary shares of URGN.

What percentage of URGN鈥檚 outstanding shares does this represent?

The stake equals 5.4% of the outstanding class.

Why was the Schedule 13G filed?

Crossing the 5% ownership threshold on 30 Jun 2025 triggered the mandatory disclosure under SEC rules.

Is Morgan Stanley an activist investor in URGN?

No. The 13G filing indicates a passive investment; Morgan Stanley states the shares are held in the ordinary course of business.

Does Morgan Stanley have sole voting power over the URGN shares?

It has 0 sole voting power; voting and dispositive authority are shared.

When was the filing signed and by whom?

The certification was signed by Chris O鈥橦ara on 06 Aug 2025.

AG真人官方

[Form 4] CrowdStrike Holdings, Inc. Insider Trading Activity

Insights

FAQ

How many UroGen Pharma (URGN) shares does Morgan Stanley hold?

What percentage of URGN鈥檚 outstanding shares does this represent?

Why was the Schedule 13G filed?

Is Morgan Stanley an activist investor in URGN?

Does Morgan Stanley have sole voting power over the URGN shares?

When was the filing signed and by whom?

NASDAQ:CRWD

CRWD Rankings

CRWD Latest News

CRWD Latest SEC Filings

CRWD Stock Data

AG真人官方

Trending News

[Form 4] CrowdStrike Holdings, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

FAQ

How many UroGen Pharma (URGN) shares does Morgan Stanley hold?

What percentage of URGN鈥檚 outstanding shares does this represent?

Why was the Schedule 13G filed?

Is Morgan Stanley an activist investor in URGN?

Does Morgan Stanley have sole voting power over the URGN shares?

When was the filing signed and by whom?

NASDAQ:CRWD

CRWD Rankings

CRWD Latest News

CRWD Latest SEC Filings

CRWD Stock Data